($\leq$ IIA/ $\geq$ IIB). All patients were treated with chemotherapy. We used Cox models with the sporadic group as the reference to obtain hazard ratios (HR) with corresponding 95% confidence intervals (CI). Since BRCA1/2 mutation carriers who received a DNA test after EOC diagnosis survived at least until this DNA test, which may result in survival bias, we also performed prospective analyses including only BRCA1/2-associated EOC patients with a DNA test result before EOC diagnosis ($n=82$) and their matched sporadic controls.

Results The mean follow-up was 4.4 years (range 0.1–30.1). For the first 5 years after EOC diagnosis, the HRs for PFS (0.85, 95% CI 0.73–0.98) and OS (0.58, 95% CI 0.49–0.69) were in favor of the BRCA1/2 EOC patients. In the prospective analyses, survival benefit withstand for PFS (HR 0.66, 95% CI 0.45–0.98), and – to a lesser extent – for OS (HR 0.69, 95% CI 0.44–1.1).

Conclusions For EOC patients treated with chemotherapy, we confirmed survival benefit for BRCA1/2 mutation carriers. This may indicate higher sensitivity to chemotherapy, both in first line treatment and in the recurrent setting.

OP019/#123

CLEAR CELL OVARIAN CANCER IN NATIVE ASIANS COMPARED TO US ASIANS – IS THERE A DIFFERENCE?

¹I Tunnage*, ²D Lewis, ³M Caesar, ⁴C-I Liao, ⁵A Chan, ⁵D Lee, ⁵A Rohatgi, ⁶K Darcy, ⁶C Tian, ^{3,7}J Chan. ¹New York University, Gynecologic Oncology, New York, USA; ²MedStar Washington Hospital Center, Obstetrics and Gynecology, Washington, USA; ³California Pacific Medical Center Research Institute, Gynecologic Oncology, San Francisco, USA; ⁴Kaohsiung Veterans General Hospital, Obstetrics and Gynecology, Kaohsiung City, Taiwan; ⁵Palo Alto Medical Foundation Research Institute, Obstetrics and Gynecology, Palo Alto, USA; ⁶Gynecologic Cancer Center of Excellence, Obstetrics and Gynecology, Washington, USA; ⁷California Pacific Medical Center, Obstetrics and Gynecology, San Francisco, USA

10.1136/ijgc-2021-IGCS.36

Objectives To study the incidence and trends of clear cell ovary cancer (CCOC) in the US and Taiwan.

Methods Data were obtained from the United States Cancer Statistics (USCS) Public Use Databases and Taiwan Cancer Registry of Taiwan Health and Welfare Data Center (HWDC) from 2001 to 2017. SEER*Stat 8.3.9, Joinpoint regression program 4.8.0.1, and Excel were used to calculate the incidence and trends.

Results Compared to Whites, Asians have nearly five-fold higher incidence of CCOC (2.44 vs 0.49 per 100,000). Native Asians have a 1.8 fold higher incidence vs. US Asians (1.58 vs. 0.86 per 100,000). The peak age range of CCOC diagnosis in Native Asians is younger compared to US women (50–54 vs. 65–69 years). From 2001 to 2017, there was an Increase in CCOC in both NAs and US Asians at 6.2% per year vs 2.1% per year, respectively. In a projected model, by 2029, the incidence of CCOC in NAs will surpass that of serous cancer in US Whites.

Conclusions Over the last 17 years the rate of clear cell ovary cancer has increased for both Asians residing in Asia and the United States and may surpass other cell types in next decade. Further studies are needed to evaluate the genetic and environmental factors responsible for this disparity.

OP020/#524

HEATH CARE RESOURCE AND COST IMPLICATIONS OF INTEGRATION OF MOLECULAR CLASSIFICATION IN THE MANAGEMENT OF ENDOMETRIAL CANCER

¹G Hanley*, ²E Thompson, ³S Scott, ⁴M Kinloch, ⁵J Irving, ⁶S Leung, ⁷S Salvador, ⁸L Helpman, ⁹D Vicus, ¹⁰A Jamieson, ¹⁰V Samouëlian, ¹¹S Kean, ¹²S offman, ¹³C Parra-Herran, ¹⁴A Talhouk, ¹⁵M Plante, ⁷W Gotlieb, ¹⁶C Gilks, ¹J Kwon, ¹J Mcalpine. ¹University of British Columbia and BC Cancer, Gynecology, Division of Gynecologic Oncology, Vancouver, Canada; ²Molecular Oncology, University of British Columbia, Vancouver, Canada; ³Dalhousie University, Obstetrics and Gynaecology, Halifax, Canada; ⁴University of Saskatchewan, Pathology and Laboratory Medicine, Saskatoon, Canada; ⁵University of British Columbia, Royal Jubilee Hospital, Pathology and Laboratory Medicine, Victoria, Canada; ⁶University of British Columbia, Genetic Pathology Evaluation Centre, Vancouver, Canada; ⁷McGill University, Jewish General Hospital, Gynecology Oncology, Montreal, Canada; ⁸Cheba medical center, Gynecologic Oncology, Ramat Gan, Israel; ⁹Sunnybrook Health Sciences Centre, Gynecologic Oncology, Toronto, Canada; ¹⁰Gynecologic Oncology Service, CHUM, Université de Montréal, Department of Obstetrics and Gynecology, Montreal, Canada; ¹¹University of Manitoba, Obstetrics and Gynecology, Gynecologic Oncology, Winnipeg, Canada; ¹²Dalhousie University, Pathology, Halifax, Canada; ¹³Brigham and Woman's Hospital, Pathology, Boston, USA; ¹⁴University of British Columbia, Obstetrics and Gynecology, Vancouver, Canada; ¹⁵Hotel Dieu de Quebec, Gynecology Oncology, Quebec, Canada; ¹⁶UBC, Vancouver General Hospital, Pathology and Laboratory Medicine, Vancouver, Canada

10.1136/ijgc-2021-IGCS.37

Objectives Increasing incidence and morbidity of endometrial cancer (EC) has resulted in high systemic cost burdens associated with management. Molecular classification is now being integrated into routine pathologic reporting, providing objective biologically-relevant data to direct care. We assessed the cost implications of this integration in a modern cohort of women with ECs.

Methods 994 women diagnosed with EC across Canada (2016) underwent retrospective molecular classification enabling us to determine their eligibility for current molecular stratification trials and 2020 ESMO/ESTRO/ESP risk group assignment and treatment recommendations. We then calculated cost differences based on molecular subtype/ProMisE-directed change in surgical management, adjuvant therapy, clinic visits, pathology testing, and genetic counseling.

Results Total costs saved, even after correcting for cost of molecular testing for all 994 individuals (\$450–\$75 CAD/test) were \$570,744–\$747,042 CAD or \$574–\$752 CAD per capita. If we test MMR and p53 IHC for all patients but perform POLE sequencing only in women where treatment would be altered (e.g., NOT testing POLE in Stage IA Grade 1/2 endometrioid ECs who are usually untreated and stage III/IV ECs where ESMO/ESTRO/ESP recommendations are currently unchanged for POLEmut ECs) total costs saved increases to \$720,294–\$958,842 or \$725–\$965/capita. If costs of additional treatment directed by ProMisE are added, such as chemotherapy +/- radiation directed secondary to unveiling high risk molecular subtype, this would be expected to improve outcomes but at an additional cost of \$280,908–\$826,719 or \$282–\$832/capita.

Conclusions Molecular classification may tailor treatment with cost savings, while providing an opportunity to improve outcomes at reasonable cost for women with endometrial carcinoma.